Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association?

J Rheumatol. 2009 Feb;36(2):462-3. doi: 10.3899/jrheum.080426.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / adverse effects*
  • Antifungal Agents / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Cryptococcosis / chemically induced*
  • Cryptococcosis / drug therapy
  • Cryptococcosis / immunology*
  • Cryptococcus neoformans / drug effects
  • Cryptococcus neoformans / immunology
  • Drug Therapy, Combination
  • Heart / microbiology
  • Heart Diseases / drug therapy
  • Heart Diseases / immunology
  • Heart Diseases / pathology
  • Humans
  • Immunocompromised Host / immunology
  • Immunosuppressive Agents / adverse effects
  • Infliximab
  • Male
  • Myocardial Perfusion Imaging
  • Myocardium / pathology
  • Sarcoidosis / drug therapy*
  • Sarcoidosis / immunology
  • Sarcoidosis / physiopathology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antibodies, Monoclonal
  • Antifungal Agents
  • Antirheumatic Agents
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab